NTHI

NEONC TECHNOLOGIES HOLDINGS, INC.

Tremor tracks 3 of its cancer trials.

Company-wide warning signs

These add points to every one of this company's trials.

None right now.

Trials

NTHINeonc Technologies, Inc.
0Calm
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Signing up patientsPhase 1/2134 patientsMain results: Feb 28, 2027
NTHINeonc Technologies, Inc.
0Calm
NEO100 and High-Grade Meningioma
Signing up patientsPhase 230 patientsMain results: Dec 30, 2026
NTHINeonc Technologies, Inc.
0Calm
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
Running, no new patientsPhase 1/249 patientsMain results: Nov 30, 2026

Key executives leaving

From the last 12 months of the company's SEC reports.

None found.

Insider trades (last 6 months)

“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.

1 sale (0 not pre-planned) · 16 purchases

Heshmatpour Amir FCEO, President · Nov 6, 2026Bought 40,000 sharesabout $136 thousand ·
Heshmatpour Amir FCEO, President · Nov 5, 2026Bought 30,000 sharesabout $95 thousand ·
GARNETT KEITHLYCFO · Sep 15, 2026Sold 5,000 sharesabout $17 thousand · pre-planned
Heshmatpour Amir FCEO, President · Sep 15, 2026Bought 35,000 sharesabout $115 thousand ·
Heshmatpour Amir FCEO, President · Sep 14, 2026Bought 15,000 sharesabout $59 thousand ·
CHEN THOMAS CCEO · Sep 14, 2026

Recent SEC filings

Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.

Money left

Coming soon: how many months of cash the company has, from its quarterly reports.